AVP and leukemia: Pharmacokinetic studies in humans indicate a relatively short half-life of ADH-1 in plasma and a low toxicity profile at all ADH-1 doses administered.23, 24, 25 Here, we reveal that clinically relevant concentrations of ADH-124 show high efficacy against a panel of 15 patient-derived leukemia samples.